01 March 2004
Gabexate mesilate and heparin responsiveness in coronary patients
Marco RanucciMed Sci Monit 2004; 10(3): PI40-43 :: ID: 11610
Abstract
Background: Heparin responsiveness in patients undergoing coronary operations changes depending on many individual factors. Reduced sensitivity to heparin is a common feature and may determine a difficult intraoperative anticoagulation. The aim of this study was to determine the effectiveness of a novel serine proteases inhibitor (gabexate mesilate) in increasing heparin responsiveness.
Material/Methods: 20 patients undergoing coronary operations with cardiopulmonary bypass were studied with respect to their heparin responsiveness. This was measured using individual dose/response tests with a heparin monitoring system before and after a 10-minute intravenous infusion of 2 mg·kg–1·h–1 of gabexate mesilate, a direct inhibitor of factor Xa, thrombin, kallikrein, and other serine proteases. The complete test was performed before initiating the surgical maneuvers.
Results: At each heparin concentration, gabexate mesilate produced a significant prolongation of the kaolin-activated clotting time. The heparin responsiveness (seconds·IU–1·ml–1) in terms of activated clotting time significantly (p=0.007) increased from the baseline of 68.1±13.8 to 74.7±16.1 during infusion, and the heparin loading dose (IU/kg) required to reach the target activated clotting time of 480 seconds significantly (p=0.009) decreased from the baseline of 290±82.3 to 260±77.6 during gabexate mesilate infusion.
Conclusions: Gabexate mesilate significantly increases individual heparin responsiveness in coronary patients. Its use in the treatment of patients with a reduced sensitivity to heparin may support or replace the conventional therapeutic approach based on fresh frozen plasma or purified antithrombin.
Keywords: Antithrombins - metabolism, Bleeding Time, Blood Coagulation, Coronary Disease - drug therapy, Factor Xa - antagonists & inhibitors, Gabexate - pharmacology, Heparin - metabolism, Heparin - pharmacology, Kallikreins - antagonists & inhibitors, Serine Proteinase Inhibitors - pharmacology, Thrombin - antagonists & inhibitors, Time Factors, Antithrombins - metabolism, Bleeding Time, Blood Coagulation, Coronary Disease - drug therapy, Factor Xa - antagonists & inhibitors, Gabexate - pharmacology, Heparin - pharmacology, Kallikreins - antagonists & inhibitors, Serine Proteinase Inhibitors - pharmacology, Thrombin - antagonists & inhibitors, Time Factors
549 1
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
08 Jun 2023 : Clinical Research
Risk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...Med Sci Monit In Press; DOI: 10.12659/MSM.940134
08 Jun 2023 : Clinical Research
A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...Med Sci Monit In Press; DOI: 10.12659/MSM.940124
08 Jun 2023 : Clinical Research
Burden of COVID-19 on Mental Health of Resident Doctors in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940208
08 Jun 2023 : Clinical Research
Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...Med Sci Monit In Press; DOI: 10.12659/MSM.940251
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952